1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,975 | 1,010 | 12:18 | |
| 0,975 | 1,010 | 11:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 13.01. | NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 | 607 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 01.12.25 | NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles | 573 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 26.11.25 | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.11.25 | NanoViricides GAAP EPS of -$0.10 | 8 | Seeking Alpha | ||
| 17.11.25 | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 358 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| 14.11.25 | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 563 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11.25 | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 612 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| 11.11.25 | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 612 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11.25 | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 623 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11.25 | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 593 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11.25 | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 503 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10.25 | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 639 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10.25 | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 667 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10.25 | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 564 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 20.10.25 | A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus | 594 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 15.10.25 | NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses | 550 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains... ► Artikel lesen | |
| 01.10.25 | NanoViricides verlängert Verträge mit Führungskräften und passt Kreditlinie an | 5 | Investing.com Deutsch | ||
| 01.10.25 | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.09.25 | NanoViricides, Inc. Has Filed its Annual Report | 793 | ACCESS Newswire | Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,600 | -2,38 % | EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
13.01.2026 / 01:04... ► Artikel lesen | |
| KOPIN | 2,758 | -6,38 % | Kopin secures $1 million contract to develop night vision upgrade module | ||
| ONTO INNOVATION | 179,00 | -2,72 % | Beyond The Numbers: 8 Analysts Discuss Onto Innovation Stock | ||
| GOMSPACE | 2,010 | -4,06 % | GomSpace Group AB: GomSpace announces 2026 market guidance with strong profitable growth | GomSpace, a leading provider of small satellite solutions, today provides an update on its 2026 financial guidance.
The company is pleased to announce comprehensive market guidance for 2026, reflecting... ► Artikel lesen | |
| VEECO INSTRUMENTS | 27,800 | -0,71 % | Veeco Instruments Inc.: Veeco Reports Third Quarter 2025 Financial Results | Third Quarter 2025 Highlights: Revenue of $165.9 million, compared with $184.8 million in the same period last yearGAAP net income of $10.6 million, or $0.17 per diluted share, compared with $22.0... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,570 | +4,59 % | FendX Technologies Inc.: FendX Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company... ► Artikel lesen | |
| CANATU | 10,050 | +11,67 % | Canatu Oyj: Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full windshield heaters | Canatu Plc Press release 2 January 2026 at 09:00 am EET
Canatu and DENSO enter Joint Development Agreement to develop large-scale CNT chamber, supporting potential automotive applications such as full... ► Artikel lesen | |
| NVE | 58,00 | 0,00 % | Dividendenbekanntmachungen (03.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,1748 USD 0,1515 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR AON PLC IE00BLP1HW54 0... ► Artikel lesen | |
| DOTZ NANO | 0,022 | -2,27 % | DOTZ NANO LIMITED: Date of AGM and Director Nominations | ||
| ZENTEK | 0,735 | -0,68 % | Zentek Ltd.: Zentek's Albany Graphite Has Demonstrated Nuclear Grade Performance in Independent Testing, Opening Pathways Into a Range of High-Return Commercial Markets | GUELPH, ON / ACCESS Newswire / January 5, 2026 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN) is pleased to announce that its wholly-owned subsidiary, Albany Graphite Corp. ("AGC")... ► Artikel lesen | |
| OBDUCAT | 0,004 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| ACACIA RESEARCH | 3,160 | 0,00 % | Acacia Research Non-GAAP EPS of -$0.01 beats by $0.13, revenue of $59.4M beats by $21.4M | ||
| ADVANCE ZINCTEK | 0,492 | 0,00 % | ADVANCE ZINCTEK LIMITED: FDA Update | ||
| LAMPETIA | 0,075 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| RIBER | 4,055 | +6,43 % | Riber receives a new order from Japan for MBE 6000 to scale Quantum Dot Laser production for Datacom | Riber receives a new order from Japan for MBE 6000 to scale Quantum Dot Laser production for Datacom. Bezons (France), 19 January 2026 - 8:00 am (CET) - RIBER, a global market leader in molecular beam... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Mit einer aktuellen Kursveränderung von -0,060 (-6,12 %) liegt der Kurs bei 0,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.